title: What non-alcoholic fatty liver disease has got to do with obstructive sleep apnoea syndrome and viceversa?
abstract: Non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnoea syndrome (OSAS) are common conditions, frequently encountered in patients with obesity and/or metabolic syndrome. NAFLD and OSAS are complex diseases that involve an interaction of several intertwined factors. Several lines of evidence lend credence to an immune system derangement in these patients, i.e. the low grade chronic inflammation status, reckoned to be the most important factor in causing and maintaining these two illnesses. Furthermore, it is emphasized the main role of spleen involvement, as a novel mechanism. In this review the contribution of the visceral adiposity in both NAFLD and OSAS is stressed as well as the role of intermittent hypoxia. Finally, a post on the prevention of systemic inflammation is made.
authors.affiliation: Department of Clinical Medicine and Surgery, Federico II University, Medical School of Naples, Naples; INT Fondazione Pascale - Cancer Research Center of Mercogliano, Mercogliano (AV). tarantin@unina.it ; giovanni.tarantino5@me.com.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Tarantino
authors.affiliation: Department of Internal Medicine, Umberto I Hospital, Nocera Inferiore, Salerno,Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Citro
authors.affiliation: Center of Obesity and Eating Disorders, Stella Maris Mediterraneum Foundation, C/da S. Lucia 80035, Chiaromonte, Potenza, Italy.
authors.forename: Carmine
authors.initials: C
authors.lastname: Finelli
mesh_terms: D050154:Adiposity; D000818:Animals; D015992:Body Mass Index; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D009765:Obesity / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D011379:Prognosis; D012307:Risk Factors; D015398:Signal Transduction; D020181:Sleep Apnea, Obstructive / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D013154:Spleen / Q000276:immunology / Q000378:metabolism
chemical_list: D018836:Inflammation Mediators